Your browser doesn't support javascript.
loading
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.
Kolonen, Aarne; Sinisalo, Marjatta; Huhtala, Heini; Rimpiläinen, Johanna; Rintala, Hannele; Sankelo, Marja; Koivunen, Elli; Silvennoinen, Raija; Räty, Riikka; Ruutu, Tapani; Volin, Liisa; Porkka, Kimmo; Jantunen, Esa; Nousiainen, Tapio; Kuittinen, Taru; Penttilä, Karri; Pyörälä, Marja; Säily, Marjaana; Koistinen, Pirjo; Kauppila, Marjut; Itälä-Remes, Maija; Ollikainen, Hanna; Rauhala, Auvo; Kairisto, Veli; Pelliniemi, Tarja-Terttu; Elonen, Erkki.
  • Kolonen A; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
  • Sinisalo M; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
  • Huhtala H; Faculty of Social Sciences, Tampere University, Tampere, Finland.
  • Rimpiläinen J; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
  • Rintala H; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
  • Sankelo M; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
  • Koivunen E; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
  • Silvennoinen R; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
  • Räty R; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
  • Ruutu T; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
  • Volin L; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
  • Porkka K; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
  • Jantunen E; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
  • Nousiainen T; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
  • Kuittinen T; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
  • Penttilä K; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
  • Pyörälä M; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
  • Säily M; Department of Medicine, Oulu University Hospital, Oulu, Finland.
  • Koistinen P; Department of Medicine, Oulu University Hospital, Oulu, Finland.
  • Kauppila M; Stem Cell Transplantation Unit, Turku University Hospital, Turku, Finland.
  • Itälä-Remes M; Stem Cell Transplantation Unit, Turku University Hospital, Turku, Finland.
  • Ollikainen H; Department of Medicine, Satakunta Central Hospital, Pori, Finland.
  • Rauhala A; The Faculty of Education and Welfare Studies, Department of Health Sciences, Åbo Akademi University, Vaasa, Finland.
  • Kairisto V; Client and Patient Safety Center, Vaasa Central Hospital, Vaasa, Finland.
  • Pelliniemi TT; Laboratory of Molecular Haematology and Pathology, Turku University Central Hospital, Turku, Finland.
  • Elonen E; Department of Clinical Chemistry, University of Turku, Finland and Fimlab Laboratories Ltd, Tampere, Finland.
Eur J Haematol ; 109(3): 257-270, 2022 Sep.
Article en En | MEDLINE | ID: mdl-35634931
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Idarrubicina / Leucemia Mieloide Aguda Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Qualitative_research / Risk_factors_studies Límite: Humans / Middle aged País como asunto: Europa Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Idarrubicina / Leucemia Mieloide Aguda Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Qualitative_research / Risk_factors_studies Límite: Humans / Middle aged País como asunto: Europa Idioma: En Año: 2022 Tipo del documento: Article